Volcano has big plans for new $36M Crux Biomedical acquisition

Mon, 12/03/2012 - 12:50pm
Mass Device

Medical device company Volcano lays out a road map to FDA wins, commercial launches and milestone payments in connection with its $36 million acquisition of Crux Biomedical.

Volcano logo

Volcano (NSDQ:VOLC) signed a definitive agreement to acquire Crux Biomedical for $36 million in cash, laying out a road map for anticipated FDA wins and commercial launches related to the merger.

Menlo Park, Calif.-based Crux Biomedical is a privately held medical device maker developing inferior vena cava filters for treatment of pulmonary embolisms, an estimated $300 million market in the U.S., according to a Volcano report.

Crux in January 2012 won FDA clearance for its inferior vena cava filter with bi-directional retrieval of blood clots, just a month after winning CE Mark approval for the European Union. Volcano is expecting to submit an FDA application for another Crux retrieval device on or before June 30, 2013.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.